Alpha 2.0
Login Register
» Authors » Richard L Hengel

Richard L Hengel

Explore the profile of Richard L Hengel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 95
Followers 0
Related Specialties
Infectious Diseases
Health Services
Hematology
Top 10 Co-Authors
H Clifford Lane
Kevin W Garey
Lucinda J Van Anglen
Julia A Metcalf
Ramesh V Nathan
Timothy E Ritter
Claudia P Schroeder
Engels N Obi
Joseph A Kovacs
Ryan J Dillon
Published In
Blood
J Infect Dis
Anaerobe
AIDS Res Hum Retroviruses
Open Forum Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers
Schroeder C, Hengel R, Nathan R, Ritter T, Obi E, Lancaster C, et al.
Anaerobe . 2022 Aug; 77:102617. PMID: 35940371
Objectives: Patients with Clostridioides difficile infection (CDI) who receive treatment at outpatient infusion centers (OICs) pose a risk for spore transmission. We investigated C. difficile contamination in the environment of...
2.
Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life
Hengel R, Schroeder C, Jo J, Ritter T, Nathan R, Gonzales-Luna A, et al.
J Patient Rep Outcomes . 2022 May; 6(1):49. PMID: 35567724
Background: Clostridioides difficile infection (CDI) is associated with high recurrence rates impacting health-related quality of life (HrQOL). However, patient-reported data are lacking particularly in the outpatient setting. We assessed changes...
3.
Real-world Experience of Bezlotoxumab for Prevention of Infection: A Retrospective Multicenter Cohort Study
Hengel R, Ritter T, Nathan R, Van Anglen L, Schroeder C, Dillon R, et al.
Open Forum Infect Dis . 2020 May; 7(4):ofaa097. PMID: 32363211
Background: Bezlotoxumab is approved for prevention of recurrence of infection (CDI) in adults receiving standard of care (SoC) therapy based on findings from MODIFY clinical trials. However, utilization practices and...
4.
Surrogate markers of immune function in human immunodeficiency virus-infected patients: what are they surrogates for?
Hengel R, Kovacs J
J Infect Dis . 2003 Dec; 188(12):1791-3. PMID: 14673756
No abstract available.
5.
Cutting edge: L-selectin (CD62L) expression distinguishes small resting memory CD4+ T cells that preferentially respond to recall antigen
Hengel R, Thaker V, Pavlick M, Metcalf J, Dennis Jr G, Yang J, et al.
J Immunol . 2002 Dec; 170(1):28-32. PMID: 12496379
Naive CD4+ T cells use L-selectin (CD62L) expression to facilitate immune surveillance. However, the reasons for its expression on a subset of memory CD4+ T cells are unknown. We show...
6.
Increasing CD4+ T cells specific for tuberculosis correlate with improved clinical immunity after highly active antiretroviral therapy
Hengel R, Allende M, Dewar R, Metcalf J, Mican J, Lane H
AIDS Res Hum Retroviruses . 2002 Sep; 18(13):969-75. PMID: 12230939
Treatment advances have led to dramatic clinical improvements for patients with HIV-1 infection. These clinical improvements reflect treatment-related improvements in immune function, which are most striking in individuals who develop...
7.
Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells
Sereti I, Martinez-Wilson H, Metcalf J, Baseler M, Hallahan C, Hahn B, et al.
Blood . 2002 Aug; 100(6):2159-67. PMID: 12200381
The long-term immunologic effects of intermittent interleukin 2 (IL-2) therapy were evaluated in a cross-sectional study by comparing 3 groups: HIV-seronegative volunteers, HIV-infected (HIV(+)) patients receiving highly active antiretroviral therapy...